Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biocad To Launch Two Biosimilars In Bosnia-Herzegovina

Forms Part Of Russian Firm's Plans For European Expansion

Executive Summary

Russia’s Biocad, with biosimilars already launched in numerous global markets, is continuing to look outward. A focus on territories in south-east Europe has seen the firm receive approvals for two biosimilars in the Balkan country Bosnia and Herzegovina.

You may also be interested in...

mRNA Vaccines – Trials Line Up Against Coronavirus

The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.

Biocad targets 80% increase in exports

Biotechnology and biosimilars specialist Biocad is seeking to increase its exports by 80% over the next few years as supply agreements for its extensive pipeline begin to deliver and additional manufacturing capacity comes onstream. To this end, the Russian company has recently struck licensing deals with companies in Greece, Mexico and the Middle East and North Africa (MENA) region.

Samsung Bioepis Added To Avastin Biosimilar Litigants

Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts